Assessing the Treatment Effect Heterogeneity with a Latent Variable by Yin, Yunjian et al.
August 30, 2018
Assessing the Treatment Effect Heterogeneity with a Latent
Variable
Yunjian Yina,b, Lan Liub,1, and Zhi Genga
aSchool of Mathematical Sciences, Peking University, Beijing 100871, China
bSchool of Statistics, University of Minnesota, Minneapolis, Minnesota 55455, USA
The average treatment effect (ATE) is popularly used to assess the
treatment effect. However, the ATE implicitly assumes a homogenous
treatment effect even amongst individuals with different characteristics.
In this paper, we mainly focus on assessing the treatment effect hetero-
geneity, which has important implications in designing the optimal indi-
vidual treatment regimens and in policy making. The treatment benefit
rate (TBR) and treatment harm rate (THR) have been defined to char-
acterize the magnitude of heterogeneity for binary outcomes. When the
outcomes are continuous, we extend the definitions of the TBR and THR
to compare the difference between potential outcomes with a pre-specified
level c. Unlike the ATE, these rates involve the joint distribution of the
potential outcomes and can not be identified without further assumptions
even in randomized clinical trials. In this article, we assume the potential
outcomes are independent conditional on the observed covariates and an
unmeasured latent variable. Under this assumption, we prove the identifi-
cation of the TBR and THR in non-separable (generalized) linear models
for both continuous and binary outcomes. We then propose estimators
and derive their asymptotic distributions. In the simulation studies, we
implement our proposed methods to assess the performance of our estima-
tors and carry out a sensitive analysis for different underlying distribution
for the latent variable. Finally, we illustrate the proposed methods in two
randomized controlled trials.
Key Words: Causal effects; Heterogeneity; Random effect; Treatment ben-
efit rate; Treatment harm rate.
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1 Introduction
The average treatment effect (ATE) is popularly used in evaluating the effect of
a treatment or intervention in a wide range of disciplines such as medicine, social
sciences, econometrics and etc. An assumption implicitly made by the ATE is the
similarity of treatment effect across heterogeneous individuals. Although this assump-
tion maybe warranted for some treatments, it is less plausible for others. For example,
most patients treated with MMR (measles, mumps, and rubella) vaccine benefit from
a very low risk of having Measles (one dose of MMR vaccine is about 93% effec-
tive while two doses are about 97% effective at preventing measles if exposed to the
virus). In contrast, clinical evidence was found that prescription of a beta-blocker
may or may not provide the desired response in treating patients with hypertension
[2]. Likewise, the prescription of anti-anxiety drugs such as Benzodiazepines may or
may not be effective in treating patients with anxiety: some patients suffer from side
effects such as drowsiness and depression while some others experienced paradoxical
reactions such as increased anxiety, irritability, and agitation.
Formally, the heterogeneity of treatment effect is present if the effect of the treat-
ment varies across subsets of individuals in a population [11]. This variability at the
individual level is also called subject-treatment interaction [8, 7]. The heterogeneity
of treatment effect may not only arise from different baseline characteristics of indi-
viduals (also known as pre-treatment heterogeneity) such as age, sex, social status
but also from distinct individual responses to a particular treatment or intervention
[3].
The importance of treatment effect heterogeneity has been frequently raised by
practical concerns. From a clinician’s perspective, the heterogeneity of treatment
effect plays an essential role in selecting the most effective treatment and designing
individualized treatment regimens [10]. Additionally, it is critical for policy makers to
understand the heterogeneity effect so as to generalize causal effect estimates obtained
from an experimental sample to a target population.
With the observed effect modifiers, the conditional ATE for different subpop-
ulations is typically calculated. In principle, such subgroup analysis would yield
homogeneous treatment effect controlling for all effect modifications. However, it is
hard to target and collect all effect modifiers based on the existing knowledge and
limited resources [20]. As a result, the residual heterogeneity stand in the way of
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better understanding the treatment effect and more effectively designing the optimal
treatment for each individual. Furthermore, the evidence of heterogeneous treatment
effect urges further pursuit of unknown effect modifiers. Novel methods are thus
of demand to assess the treatment effect heterogeneity of the study population or
subpopulation.
To better illustrate the treatment effect heterogeneity, we use the framework of
potential outcomes [13, 12, 9]. Under this framework, each individual has a po-
tential outcome for every possible treatment, and the individual level effect of an
experimental treatment relative to a control is defined by a comparison between the
corresponding potential outcomes. However, for each individual, only one potential
outcome, the one corresponds to the actual treatment, can be observed in practice.
Under the potential outcomes framework, the treatment benefit rate (TBR) and
the treatment harm rate (THR) have been defined to assess the treatment effect
heterogeneity [6, 8, 7, 1, 11, 15, 20]. More specifically, when the outcomes are binary,
the TBR (THR) is defined as the rate of people who have a better (worse) outcome
if given the treatment compared with control. The TBR and THR can be similarly
defined for continuous outcomes by comparing the difference between the potential
outcomes with some level c. Note that the definitions of the TBR and THR involve
the joint distribution of the two potential outcomes, thus can not be identified without
further assumptions even in randomized trials.
There is a growing number of literature deriving the bounds for the TBR and
THR. Gadbury et al. [7] derived the simple bounds of the THR by only using the
observed data without further assumptions. Additionally, they derived tighter bounds
by estimating the quality of matching in a matched design. Albert et al. [1] extended
the method to a block trial which includes the matched trial as a special case. Under
the assumption that subjects are exchangeable within blocks and that the within-
block probabilities are constant across blocks, they estimated the bounds and provided
the variances for the estimators. Alternatively, Yin and Zhou [18] used a secondary
outcome to obtain tighter bounds under the monotonicity, transitivity and causal
necessity assumptions.
Other attempts have also been made to identify and estimate the TBR and THR
under independence assumptions. Shen et al. [15] and Zhang et al. [20] assumed
that the two potential outcomes were independent conditional on observed covariates.
However, this assumption is stringent in practice since the two potential outcomes are
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from the same individual and there is no guarantee that all the observed covariates
are sufficient to explain the dependence. Yin et al. [19] estimated the TBR and THR
assuming the existence of at least three covariates which are mutually independent
in the subgroup defined by the joint distribution of the potential outcomes. Their
assumption could be tested when more than three such covariates were available
without any modeling assumptions. However, it is hard to find such covariates in
practice and extend the method to the case with continuous outcomes.
In this article, we assume that the potential outcomes are independent given the
observed covariates and an unmeasured latent variable. This assumption is weaker
than the independence assumption made by Shen et al. [15] and Zhang et al. [20] and
is much more reasonable in practice. Under non-separable (generalized) linear mod-
els, we prove the identification and construct estimators using maximum-likelihood
estimation (MLE). We also derive the asymptotic distribution and variance for the
estimators.
We organize the paper as follows. In Section 2, we introduce the notations and
describe the assumptions. In Section 3, we provide identification conditions for the
TBR and THR under non-separable models for continuous and binary outcomes.
The estimators and their asymptotic properties are derived in Section 4. We report
the simulation results in Section 5. Then we illustrate our proposed method in two
randomized trials in Section 6. The paper concludes with a discussion in Section 7.
2 Preliminaries
Let T denote a binary treatment assignment variable which is completely ran-
domized and let Y denote a primary outcome of interest. Let X = (X1, · · · , Xp)T
denote p-dimensional observed covariates, where the superscript T denotes transpo-
sition. Let t denote a possible value T could take (t = 1 for treatment and t = 0 for
placebo). Assume larger value of Y indicates better response. Under the Stable Unite
Treatment Value Assumption (SUTVA) [14], we denote Y1 and Y0 as the potential
outcomes under treatment and control, respectively.
When the outcome variable Y is binary, Shen et al. [15] defined the TBR and
THR as
TBR = P (Y0 = 0, Y1 = 1) and THR = P (Y0 = 1, Y1 = 0).
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We can also define the TBR (THR) for subpopulation with specific covariates X as
TBR(X) = P (Y0 = 0, Y1 = 1|X). For the simplicity of illustration, we only focus
on the population TBR and THR here. The inference for the TBR and THR in the
subpopulation could be derived in a similar fashion. Note the TBR is the proportion of
individuals in the population that have a better outcome if given treatment compared
to control. In contrast, the THR is the proportion of individuals in the population
that have a better outcome if given control compared to treatment. Note that when
the outcomes are binary, the ATE corresponds to the difference between the TBR
and the THR, which not only provide information about the overall treatment effect
but also how treatment effect may vary across individuals. When Y is continuous, we
extend the definition of the TBR and the THR by comparing the difference between
the potential outcomes with some level c. More specifically, define:
TBRc = P (Y1 − Y0 > c) and THRc = P (Y0 − Y1 > c),
where c is a pre-specified constant. Again, TBRc and THRc can be defined anal-
ogously for subpopulation with specific covariates values, e.g., define TBRc(X) =
P (Y1−Y0 < c|X). Note that TBRc is the proportion of individuals in the population
whose outcome Y would benefit greater than c from the treatment compared with
the control and THRc is the proportion of the individuals whose outcome Y would
be harmed by at least c by the treatment compared with the control.
Due to the randomization, we can identify the marginal distributions of Y0, Y1 as
well as ATE = E(Y1−Y0). However, as mentioned previously, the TBR, THR, TBRc
and THRc involve the joint distribution of the two potential outcomes, thus can not
be identified even in randomized trails without any further assumption. To make
progress, Shen et al. [15] and Zhang et al. [20] made the following assumption.
Assumption 1. (Conditional Independence) Y0⊥Y1|X.
Assumption 1 states that the two potential outcomes are independent conditional
on a set of observed relevant baseline covariates. Hence, the joint distribution of
Y0 and Y1 can be identified by factorization, i.e., P (Y0, Y1|X) = P (Y0|X)P (Y1|X).
However, this assumption requires the collection of all relevant covariates X to con-
trol for the dependency between two potential outcomes, which is hard to satisfy in
practice and impossible to test from the observed data. Alternatively, we make the
following assumption by assuming the independence between the potential outcomes
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conditional on observed covariates X as well as a latent variable U .
Assumption 2. (Latent Independence) Y0⊥Y1|(X,U), U⊥X.
Note that Assumption 1 is a special case of Assumption 2 when there is no latent
variable U , i.e., U ∈ ∅. Also note that the independence between X and U can be
satisfied by orthogonalization of U with respect to X [20]. Additionally, Zhang et al.
[20] claimed that under Assumption 2, the information of U is not identifiable in a
generalized linear mixed model (GLMM) and thus adopted a sensitivity analysis.
3 Identification
In this section, we derive the identification for the TBR and the THR under non-
separable GLMM for both continuous and binary outcomes. More specifically, we
have the following model for continuous outcomes:{
Yt = αt,0 + α
T
t,1X + αt,2U + α
T
t,3XU + t,
t⊥(X,U), t ∼ N(0, σ2t ), U ∼ N(µU , σ2U), αt,3 6= 0,
(1)
for t = 0, 1, where αt,1 = (α
(1)
t,1 , · · · , α(p)t,1 )T , αt,3 = (α(1)t,3 , · · · , α(p)t,3 )T . Without loss
of generality, we can assume αt,2 > 0 since otherwise set U
∗ = sign(αt,2) · U and
α∗t,2 = sign(αt,2) · αt,2, where sign(k) denotes the sign of k. Note that αt,3 6= 0
indicates that the model is not separable, i.e., the model can not be written in the
form of Yt = l1(X)+l2(U). This is not a very stringent assumption especially when the
observed covariates X is high dimensional since we only require at least one but not
all interactions between X and U . Especially the existence of the interaction can be
tested by checking whether αt,3 is significant with the observed data, although U is a
latent variable. Note that the latent variable U can be interpreted as a subject specific
random effect and the distribution of U is assumed to be normal distribution. We
will test how the identification and estimation method perform when the normality
assumption of U is violated in a sensitivity analysis in Section 5. Also without loss
of generality, we can assume (µU , σ
2
U) = (0, 1) since otherwise U can be standardized.
Note that the inclusion of U in the model (1) can be tested by checking whether
that the coefficients (αt,2, αt,3, t = 0, 1) are significant. If there are at least one of them
is significant in the models for both Y0 and Y1, then the Assumption 1 is violated and
we must include a latent U to make the conditional independence of Y0 and Y1 to
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hold.
Note that we have the following formulas (F1)-(F2) for TBRc and THRc, the
proofs of which are given in the supplementary material. From (F1)-(F2), we know
that once the parameters in model (1) are identified, the TBRc and THRc can also
be identified. Specifically,
TBRc =
∫
Φ
( (α1,0 − α0,0) + (α1,1 − α0,1)Tx− c√(
(α1,2 − α0,2) + (α1,3 − α0,3)Tx
)2
+ σ20 + σ
2
1
)
fX(x)dx, (F1)
THRc =
∫
Φ
( (α0,0 − α1,0) + (α0,1 − α1,1)Tx− c√(
(α0,2 − α1,2) + (α0,3 − α1,3)Tx
)2
+ σ20 + σ
2
1
)
fX(x)dx, (F2)
where fX(·) is the density of X, Φ(·) is the cumulative distribution function of a
standard normal variable.
When outcomes are binary, we consider the following model:
Y ∗t = αt,0 + α
T
t,1X + αt,2U + α
T
t,3XU + t,
Yt = I(Y
∗
t > 0),
t⊥(X,U), t ∼ N(0, σ2t ), U ∼ N(µU , σ2U), (αt,0, αt,1) 6= 0, αt,3 6= 0,
(2)
for t = 0, 1, where αt,1 = (α
(1)
t,1 , · · · , α(p)t,1 )T , αt,3 = (α(1)t,3 , · · · , α(p)t,3 )T . Again, we assume
that U follows the standard normal distribution. Additionally, without loss of gen-
erality, we can assume σ20 = σ
2
1 = 1 since otherwise set Y
∗∗
t = Y
∗
t /σt, αt,k = αt,k/σt,
and ∗t = t/σt for t = 0, 1 and k = 0, 1, 2, 3. Note that Y
∗ is a latent variable and (2)
indicates a probit model for the outcome Y , i.e.,
P (Yt = 1|X,U) = Φ
(
αt,0 + α
T
t,1X + αt,2U + α
T
t,3XU
)
.
Also, similar to the continuous model (1), the inclusion of U and the interaction
terms can be tested by checking corresponding coefficients are significant.
Note that we have the following formulas (F3)-(F4) for TBR and THR, the proofs
of which are given in the supplementary material. From (F3)-(F4), we know that once
the parameters in model (2) are identified, the TBR and THR can also be identified.
Specifically,
TBR =
∫
Φb
(
µ(x; θ),Σ(x; θ)
)
fX(x)dx, (F3)
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and
THR =
∫
Φh
(
µ(x; θ),Σ(x; θ)
)
fX(x)dx, (F4)
where
µ(x; θ) =
(
µ0(x; θ), µ1(x; θ)
)
=
(− α0,0 − αT0,1x, − α1,0 − αT1,1x),
Σ(x; θ) =
(
1 + (α0,2 + α
T
0,3x)
2 (α0,2 + α
T
0,3x)(α1,2 + α
T
1,3x)
(α0,2 + α
T
0,3x)(α1,2 + α
T
1,3x) 1 + (α1,2 + α
T
1,3x)
2
)
.
Φb
(
µ,Σ
)
= Φ2
(
(0,∞), (−∞, 0);µ,Σ),
Φh
(
µ,Σ
)
= Φ2
(
(−∞, 0), (0,∞);µ,Σ),
and Φ2(A0, A1;µ,Σ) is the distribution function of bivariate normal vector with mean
µ, covariance matrix Σ in the integration region A0 × A1, i.e.,
Φ2(A0, A1;µ,Σ) =
∫ ∫
A0×A1
1
2pi|Σ|1/2 exp
{−1
2
(s0−µ0, s1−µ1)Σ−1(s0−µ0, s1−µ1)T
}
ds0ds1.
Let θ = (θT0 , θ
T
1 )
T denote the parameters in models (1) and (2). More specifically,
let θt = (αt,0, α
T
t,1, αt,2, α
T
t,3, σ
2
t )
T in the continuous model and θt = (αt,0, α
T
t,1, αt,2, α
T
t,3)
T
in the binary model, for t = 0, 1. We can have the following theorem for the identifi-
cation of θ and thus the identification of (TBRc, THRc) for the continuous outcomes
and (TBR, THR) for the binary outcomes, the proof of which is given in the supple-
mentary material.
Theorem 1. Under Assumption 2,
(i) If the model (1) holds for continuous outcomes, the parameters θ can be iden-
tified, thus the TBRc and THRc can also be identified for any constant c.
(ii) If the model (2) holds for binary outcomes and the regularity Condition C.
(given in the supplementary material) holds, the parameters θ can be identified,
thus the TBR and THR can also be identified.
Theorem 1 states the identification of GLMM for both continuous and binary out-
comes under a relaxed conditionally independence of potential outcomes conditional
on observed covariates and a latent variable U . Note that the non-separable condition
plays an important role in the identification of the parameters θ in the presence of
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U . When marginalizing over U , the interaction term between U and X helps identify
the effect of U on Y which would otherwise be absorbed in intercept.
Note that the covariates X are in their linear terms in model (1) and (2). However,
this is not required for the identification purpose. When the outcomes are continuous,
the general form of the GLMM is{
Yt = gt(X) + Uht(X) + t,
t⊥(X,U), t ∼ N(0, σ2t ), U ∼ N(0, 1),
(3)
for t = 0, 1. Similarly, when the outcomes are binary, the general form of a GLMM is
Y ∗t = gt(X) + Uht(X) + t,
Yt = I(Y
∗
t > 0),
t⊥(X,U), t ∼ N(0, 1), U ∼ N(0, 1),
(4)
for t = 0, 1. Note that (1) and (2) are special case of (3) and (4) with gt(X) =
αt,0 + α
T
t,1X and ht(X) = αt,2 + α
T
t,3X. In the supplementary material, we give the
necessary and sufficient conditions to identify θ = (g0(X), h0(X), σ
2
0, g1(X), h1(X), σ
2
1)
in model (3) and θ = (g0(X), h0(X), g1(X), h1(X)) in model (4). Note that once
(h0(X), h1(X)) can be identified, we can test the inclusion of U by testing whether
(h0(X), h1(X)) is significant with the observed data.
4 Inference
We now propose estimators for TBR and THR and derive their asymptotic prop-
erties.
4.1 Continuous Outcomes
Note that θ can be estimated by the MLE θ̂ which is obtained by maximizing the
log-likelihood,
` = logL(T,X, Y ) = Pn
{
ψ(T,X, Y ; θ)
}
,
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where Pn is the empirical mean, i.e., Png(X) =
∑n
i=1 g(Xi)/n, and
ψ(T,X, Y ; θ)
=
∑
t=0,1
1
2
[
I(T = t)
{
− log(2pi)− log ((αt,2 + αTt,3X)2 + σ2t )− (Y − αt,0 − αTt,1X)2(αt,2 + αTt,3X)2 + σ2t
}]
.
Thus we have the asymptotic normality of
√
n(θ̂ − θ), which can be used to test the
significant of the parameters. Following (F1) and (F2), we can estimate the TBRc
and THRc by
T̂BRc = PnΦ
( (α̂1,0 − α̂0,0) + (α̂1,1 − α̂0,1)TX − c√(
(α̂1,2 − α̂0,2) + (α̂1,3 − α̂0,3)TX
)2
+ σ̂20 + σ̂
2
1
)
,
T̂HRc = PnΦ
( (α̂0,0 − α̂1,0) + (α̂0,1 − α̂1,1)TX − c√(
(α̂0,2 − α̂1,2) + (α̂0,3 − α̂1,3)TX
)2
+ σ̂20 + σ̂
2
1
)
,
where α̂t,k and σ̂t2 are MLEs for the corresponding parameters. The following
theorem shows the
√
n consistency, asymptotic normality and provides the asymptotic
variance of the estimators when the outcomes are continuous.
Theorem 2. If the model (1) holds for continuous outcomes, we can have
√
n
(
T̂BRc − TBRc
) d−→ N(0, σ2cB(θ)),
√
n
(
T̂HRc − THRc
) d−→ N(0, σ2cH(θ)),
where
d−→ denotes convergence in distribution. The proof of Theorem 2 and the
expressions and consistent estimators of σ2cB(θ) and σ
2
cH(θ) are given in the supple-
mentary material.
4.2 Binary Outcomes
Note that θ can be estimated by the MLE θ̂ which is obtained by maximizing the
log-likelihood,
` = logL(T,X, Y ) = Pn
{
ψ(T,X, Y ; θ)
}
,
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and
ψ(T,X, Y ; θ) =
∑
t=0,1
[
I(T = t)
{
Y log
(
G(X; θt)
)
+ (1− Y ) log (1−G(X; θt))}],
where
G(X; θt) = Φ
( αt,0 + αTt,1X√
1 + (αt,2 + αTt,3X)
2
)
.
Similarly, we can have the asymptotic normality of
√
n(θ̂ − θ), which can be used to
test the significant of the parameters. Following (F3) and (F4), we can estimate TBR
and THR by
T̂BR = PnΦb
(
µ(X; θ̂),Σ(X; θ̂)
)
,
T̂HR = PnΦh
(
µ(X; θ̂),Σ(X; θ̂)
)
.
The following theorem shows the
√
n consistency, asymptotic normality and pro-
vides the asymptotic variance of the estimators when the outcomes are binary.
Theorem 3. If the model (2) holds for binary outcomes and the regularity
Condition C. holds, we have
√
n
(
T̂BR− TBR) d−→ N(0, σ2bB(θ)),
√
n
(
T̂HR− THR) d−→ N(0, σ2bH(θ)).
The expressions and consistent estimators of σ2bB(θ) and σ
2
bH(θ) are given in the
supplementary material.
5 Simulation
5.1 The performance of the estimators
We first assess the performance of the estimators proposed in Section 4. The
simulations were conducted under two scenarios: (a) the continuous outcomes and
(b) the binary outcomes. For scenario (a), the simulation study was conducted in the
following steps:
Step 1: A population of sample size 1000 was created. Variables T , X and U were
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generated independently. More specifically, treatment T was generated from a
Bernoulli distribution with P (T = 1) = 0.5, the components of covariates X =
(X1, X2, X3)
T were identically and independently generated from a standard
normal distribution and latent variable U was also generated from standard
normal distribution. Potential outcomes (Y0, Y1) were generated from model
(1) with the parameters set to:
(α0,0, α
(1)
0,1, α
(2)
0,1, α
(3)
0,1, α0,2, α
(1)
0,3, α
(2)
0,3, α
(3)
0,3) = (−0.3, 1.2,−1.0,−0.8, 0.7,−0.5, 1.3, 0.6),
(α1,0, α
(1)
1,1, α
(2)
1,1, α
(3)
1,1, α1,2, α
(1)
1,3, α
(2)
1,3, α
(3)
1,3) = (0.2,−0.8, 1.2, 1.0, 0.8,−0.6, 1.0, 0.6),
σ20 = 1.0, σ
2
1 = 1.2.
Step 2: The parameters θ was estimated using MLE and the estimates of (TBRc,THRc)
and the variances of the estimators were obtained, where c = 1.
Step 3: Steps 1 and 2 were repeated for 1000 times to obtain the biases, average esti-
mated standard error (ASE) and the empirical standard error (ESE).
The results are reported in Table 1 where U was simulated from a normal distribution.
From the table we can see that the biases are -0.001 and 0.003 for TBRc and THRc
respectively, and the ASE are 0.017 and 0.015 respectively, which both approximate
their ESE. Also note that the coverages of the 95% CI approximate 0.95 indicating
the good performance of our estimators.
For the scenario (b), the simulation process is similar to that for scenario (a),
except: in Step 1, we set the sample size to be 2000 and generate (Y0, Y1) from model
(2) with the same θ excluding (σ20, σ
2
1) and in Step 2, the (TBR, THR) were calculated
instead of the (TBRc,THRc). The results for the binary outcomes are shown in Table
2 where U is simulated from a normal distribution. From the table we can see that the
biases are 0.001 and 0.001 for TBR and THR respectively, and the ASE are 0.016 and
0.013 respectively, which both approximate their ESE. Similarly, as in the scenario
(a), the coverages of the 95% CI approximate 0.95 indicating good performance of
our estimators.
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Table 1: The true value, bias, average estimated standard error (ASE), empirical
standard error (ESE) and 95% confidence interval (CI) coverage in continuous case.
Every table cell contains two elements, which corresponds to TBRc (first row in each
cell) and THRc (second row in each cell) (c = 1) respectively.
Distribution of U true value bias ASE ESE 95% CI coverage
Normal
0.450 -0.001 0.017 0.017 0.935
0.346 0.003 0.015 0.015 0.942
t(3)
0.448 -0.001 0.017 0.017 0.949
0.347 0.004 0.015 0.016 0.935
t(10)
0.448 -0.000 0.017 0.017 0.951
0.345 0.005 0.015 0.015 0.937
χ2(3)
0.448 0.001 0.017 0.016 0.949
0.349 0.002 0.015 0.015 0.953
χ2(10)
0.448 -0.000 0.017 0.017 0.951
0.346 0.005 0.015 0.015 0.938
P(3)
0.449 0.000 0.017 0.017 0.950
0.348 0.002 0.015 0.015 0.944
P(10)
0.448 0.001 0.017 0.017 0.937
0.345 0.004 0.015 0.015 0.928
B(0.5)
0.450 -0.000 0.017 0.017 0.955
0.349 0.000 0.015 0.015 0.955
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Table 2: The true value, bias, average estimated standard error (ASE), empirical
standard error (ESE) and 95% confidence interval (CI) coverage in continuous case.
Every table cell contains two elements, which corresponds to TBR (first row in each
cell) and THR (second row in each cell) respectively.
Distribution true value bias ASE ESE 95% coverage
Normal
0.363 0.001 0.016 0.016 0.947
0.241 0.001 0.013 0.013 0.956
t(3)
0.339 0.002 0.015 0.015 0.943
0.305 0.001 0.013 0.014 0.948
t(10)
0.306 0.001 0.016 0.015 0.954
0.294 0.001 0.014 0.013 0.955
χ2(3)
0.315 0.002 0.016 0.016 0.941
0.301 0.002 0.014 0.014 0.945
χ2(10)
0.302 0.000 0.016 0.016 0.947
0.297 0.000 0.014 0.014 0.949
P(3)
0.297 0.000 0.016 0.016 0.951
0.295 0.000 0.014 0.013 0.955
P(10)
0.297 4e-04 0.016 0.016 0.954
0.294 6e-04 0.014 0.013 0.954
B(0.5)
0.243 0.004 0.017 0.016 0.941
0.288 -0.000 0.014 0.015 0.943
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5.2 Sensitive analysis with respect to the distribution of U
We assumed that U is normally distributed for the identification of the joint dis-
tribution of (Y0, Y1). Since U is unobserved, its actual distribution is unknown which
may or may not be normal. We carry out a sensitivity analysis to evaluate the per-
formance of the estimators for TBR and THR under different underlying distribution
of U . We consider the following underlying distribution for U : t-distribution, chi-
squared, Poisson and Bernoulli. The estimation was carried out the same as section
5.1 except U is generated from the distributions above. Note that we standardized U
to have mean 0 and variance 1 under different distributions.
The results when the outcomes are continuous are shown in Table 1. When U is
generated from t(3), the biases are -0.001 and 0.004 for TBRc and THRc respectively,
and the ASE are 0.017 and 0.015 respectively, which approximate to the ESE. Also,
the coverages of 95% CI are 0.949 and 0.935 respectively, which approximate 0.95.
Similar performance was also observed when U follows other distributions such as
chi-squared, Poisson and Bernoulli. Note that as the degree of freedom increases in
distributions such as chi-squared, Poisson, the standardized U can be approximated
by a normal distribution. Thus the good performances of estimators under these
distributions were expected. But when the degree of freedom is small, the perfor-
mance of estimators are robust for both symmetric distributions (e.g., t-distribution)
and skewed distributions (e.g., chi-squared distribution). Moreover, the estimators
are robust even for the discrete distribution (Poisson, Bernoulli). Also, the ASE
approximate to the ESE under different distributions of U .
The results of the binary case are shown in Table 2. When U follows a t(3)
distribution, the biases are 0.002 and 0.001 for TBR and THR respectively, and
the ASE are 0.015 and 0.013 respectively, which approximate to the ESE. Also, the
coverages are 0.943 and 0.948 respectively, which approximate 0.95. From the table
we can also conclude that when the outcomes are binary, the estimators are still
robust to the different distribution of unmeasured variable U including symmetric,
non-symmetric and discrete distribution.
6 Real data analysis
We illustrate our methods in two randomized controlled trials.
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6.1 The Effect of Arnica 30× in Alleviating DOMS
The delayed-onset muscle soreness (DOMS) is commonly experienced muscle ten-
derness or debilitating pain after exercising. The soreness usually reaches its peak in
24-48 hours after exercise. Despite the prevalence of DOMS, it still remains unclear
about the mechanisms, treatment, and how it affects the athletic performance [4].
A randomized, double-blinded placebo-controlled trial was carried out to deter-
mine whether homeopathic Arnica 30× can be beneficial for DOMS following long-
distance running [17]. A total of 519 runners were randomized to either Arnica 30×
or an indistinguishable placebo. The data results were obtained from 400 individuals
while the rest 119 individuals did not run or were lost to follow up. Despite the miss-
ing data, the remaining 400 subjects were still considered to be randomized due to the
double-blind design and well balanced baseline covariates distributions for treatment
and control groups. The primary outcome measure was mean 11-point visual analog
score (VAS) for the 2-day period after the run. The VAS score is continuous and
ranges from 0 to 100, where the higher the VAS score indicates more muscle soreness.
It has been found that the mean VAS score is 4.15 mm lower in the placebo group
(95% CI: (-0.51, 8.81)). Note that 0 is contained in the CI thus suggesting that that
there is no significant effect of Arnica 30× in alleviating the DOMS.
Usually in a study with a non-significant ATE, there is still concern that if the
treatment is beneficial to some individuals, we may still need to make such treatment
as an option available for these who benefits. Let Y = 100− VAS to guarantee that
larger value of Y indicates better response. Let “age”, “sex”, “tr”, “le”, “inj” and
“rt” denote the age, gender, training miles, length of race, whether injured and race
time of the individuals. Since these six variables are all possibly related to the DOMS,
we include them in model (1). The results of the regression suggest some significant
interactions, including U· inj (α̂(5)0,3 = −6.58, P = 0.004, 95% CI: (-11.50, -1.66)), U·
tr (α̂
(3)
1,3 = 0.18, P = 0.008, 95% CI: (0.04, 0.32)), U· le (α̂(4)1,3 = −0.72, P = 0.025, 95%
CI: (-1.43,-0.02)), U· rt (α̂(6)1,3 = 0.06, P = 0.030, 95% CI: (0.01, 0.12)). This justifies
the inclusion of U in the model (1) and the non-separable assumption holds. We then
estimated the TBRc and THRc over a range of pre-specified constant c. The results
are shown in Table 3.
Note that the 95% confidence intervals of TBRc always contain 0, which means the
Arnica 30× may not be beneficial to anyone. Note when c = 0, we have T̂HRc = 0.70
with a 95% confidence interval (0.33, 1.00) excluding 0. This indicates that at least
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Table 3: Estimates and 95% confidence intervals for TBRc and THRc with different
values of pre-specified constant c for the study of treatment effect of Arnica 30× on
DOMS
TBRc THRc
c Estimate 95% CI Estimate 95% CI
0 0.30 (0.00, 0.67) 0.70 (0.33, 1.00)
2 0.19 (0.00, 0.49) 0.55 (0.17, 0.92)
4 0.11 (0.00, 0.33) 0.39 (0.04, 0.74)
6 0.07 (0.00, 0.20) 0.25 (0.00, 0.59)
8 0.04 (0.00, 0.13) 0.16 (0.00, 0.44)
10 0.02 (0.00, 0.08) 0.10 (0.00, 0.28)
12 0.01 (0.00, 0.05) 0.07 (0.00, 0.18)
14 0.01 (0.00, 0.03) 0.05 (0.00, 0.14)
16 0.01 (0.00, 0.02) 0.04 (0.00, 0.10)
18 0.00 (0.00, 0.01) 0.03 (0.00, 0.08)
20 0.00 (0.00, 0.01) 0.02 (0.00, 0.06)
33% of individual have worse outcome if given Arnica 30× as compared with control.
Such harmful effect rate decreases as c increase and goes away when we set c ≥ 6. In
this study, since there is no subgroup of individual that might benefit from Arnica
30× and some portion of individuals that might have slightly more soreness using it.
Thus, we reach the conclusion that there is no significant evidence support the use of
using Arnica 30× to alleviate DOMS.
6.2 ACCORD Eye Study
The diabetic retinopathy (DR) is one of the most common causes of vision loss
among people with diabetes and the leading cause of vision impairment and blindness
among adults younger than 65 years old in the United States [5]. It has been found
that poor glycemic control is one of the most important risk factors associated with
the development of DR. The Action to Control Cardiovascular Risk in Diabetes (AC-
CORD) study group enrolled 10,251 participants with type 2 diabetes who were at
high risk for cardiovascular disease to randomly receive either intensive or standard
treatment for glycemia randomly (target glycated hemoglobin level, < 6.0% or 7.0
to 7.9%, respectively [16]. Among those participants, there were 2856 of them were
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eligible for the ACCORD Eye study. The ACCORD Eye study aimed at determining
whether the intensive glycemia could reduce the risk of development or progression
of diabetic retinopathy, as compared with the standard treatments. The primary
outcome of this study was the composite end point of either progression of diabetic
retinopathy by at least three steps on the Early Treatment Diabetic Retinopathy
Study (ETDRS) Severity Scale or development of proliferative diabetic retinopathy
necessitating photocoagulation therapy or vitrectomy in 4 years [16]. Since the inter-
vention in the original study is randomized and the inclusion criteria did not affect
the intervention, the ACCORD Eye study can still be considered as a randomized
trial.
At the end of 4 years of follow-up, progression of diabetic retinopathy was seen
in 7.3% of participants (104 out of 1429) in the intensive glycemic control group,
as compared with 10.4% of participants (149 out of 1427) in the standard glycemic
therapy group. Using the same notation as in Section 2, we denote Y = 0 if the
progression of diabetic retinopathy was seen, and Y = 1 otherwise. Thus the ATE=
0.032 (P = 0.003, 95% CI, 0.011 to 0.052) suggesting a significant effect of the intensive
glycemic control.
Usually in a study with significant ATE, there is still concern that the active
treatment might be harmful for some individuals, thus we may need to proceed with
caution when providing them with such intervention. To estimate the TBR and THR,
we adjust in model (2) for other treatments that patients are using with indicator
variables, denote as (X1, X2, X3, X4). This set of covariates were also considered by
Group and Group [16] in their models. The results of the regression suggest some
significant interactions, including U·X1 (α̂(1)0,3 = 0.56, P = 0.021, 95% CI: (0.24, 0.87)),
U·X2 (α̂(2)1,3 = 0.53, P = 0.027, 95% CI: (0.21, 0.85)). This justifies the inclusion of
U in the model (2) and the non-separable assumption holds. The estimates for TBR
and THR are 0.078 and 0.046 with their standard errors 0.006 and 0.005 respectively
(p-value both < 0.0001). Thus it is suggested that there are 7.8% of people benefit
from the intensive glycemia control while 4.6% of people get harmed from intensive
glycemia control.
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7 Discussion
In this article, we assessed the treatment effect heterogeneity by evaluating the
TBR and the THR. We relaxed the conditional independence Assumption 1 by al-
lowing the presence of an unmeasured latent variable. Under our non-separable (gen-
eralized) linear models, the existence of the latent variable can be tested, and then
we provided identification and estimation methods. The models we used require an
interaction term between the latent variable and at least one covariate, which is likely
to hold when covariates X is high dimensional and can also be tested by the observed
data. It can be shown that the parameters are not identifiable in the absence of such
interaction due to the presence of unmeasured latent variable.
We imposed a normality assumption of the latent variable U . The normality of
U is not necessary for identification purpose, but when the distribution of U is not
normal, the distribution of Y − g(X) conditional on X may not have a distribution
in closed form and the identification condition may thus be complicated. We carried
out a sensitivity analysis to evaluate the performance of estimators under different
underlying distribution of U . We leave the generalization of identification and esti-
mation of treatment effect heterogeneity under different distribution of U as future
research topic.
In our simulation studies, the estimation procedures are almost convergent for the
cases of continuous outcomes, although they may not be so for a few cases of binary
outcomes. For example, when the sample size is 2000, for binary outcomes, when the
underlying distributions of U is actually normal, we observed 0.9% of non-convergence
and when we do sensitivity analysis of U ’s distribution, the non-convergence is 5.8%
for chi-squared distribution. Such non-convergence disappear when sample size is
increased. Also, there was no such non-convergence observed for continuous outcomes
in the simulation.
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